Follow
Yann Abraham
Title
Cited by
Cited by
Year
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
M Bantscheff, D Eberhard, Y Abraham, S Bastuck, M Boesche, S Hobson, ...
Nature biotechnology 25 (9), 1035-1044, 2007
12032007
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
M Bantscheff, C Hopf, MM Savitski, A Dittmann, P Grandi, AM Michon, ...
Nature biotechnology 29 (3), 255-265, 2011
7742011
YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors
P Marti, C Stein, T Blumer, Y Abraham, MT Dill, M Pikiolek, V Orsini, ...
Hepatology 62 (5), 1497-1510, 2015
2112015
High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions
D Hoepfner, SB Helliwell, H Sadlish, S Schuierer, I Filipuzzi, S Brachat, ...
Microbiological research 169 (2-3), 107-120, 2014
1642014
A role for centrin 3 in centrosome reproduction
S Middendorp, T Küntziger, Y Abraham, S Holmes, N Bordes, M Paintrand, ...
The Journal of Cell Biology 148 (3), 405-416, 2000
1392000
High‐parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action
HC Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Smets, J Bald, ...
Cytometry Part A 95 (3), 279-289, 2019
1322019
Target of rapamycin complex 2 regulates actin polarization and endocytosis via multiple pathways
D Rispal, S Eltschinger, M Stahl, S Vaga, B Bodenmiller, Y Abraham, ...
Journal of Biological Chemistry 290 (24), 14963-14978, 2015
872015
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
T Casneuf, HC Adams III, NWCJ van de Donk, Y Abraham, J Bald, ...
Leukemia 35 (2), 573-584, 2021
802021
Multiparametric analysis of screening data: growing beyond the single dimension to infinity and beyond
Y Abraham, X Zhang, CN Parker
Journal of biomolecular screening 19 (5), 628-639, 2014
412014
Jenkins-CI, an open-source continuous integration system, as a scientific data and image-processing platform
IK Moutsatsos, I Hossain, C Agarinis, F Harbinski, Y Abraham, L Dobler, ...
SLAS DISCOVERY: Advancing Life Sciences R&D 22 (3), 238-249, 2017
342017
Exploring Glucocorticoid Receptor Agonists Mechanism of Action Through Mass Cytometry and Radial Visualizations
Y Abraham, B Gerrits, MG Ludwig, M Rebhan, C Gubser Keller
Cytometry Part B: Clinical Cytometry 92 (1), 42-56, 2017
182017
NK cell phenotype is associated with response and resistance to daratumumab in relapsed/refractory multiple myeloma
CPM Verkleij, KA Frerichs, MEC Broekmans, C Duetz, CA O’Neill, ...
Hemasphere 7 (5), e881, 2023
162023
Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector memory T …
NWCJ Van de Donk, H Adams III, G Vanhoof, J Krejcik, K Van der Borght, ...
Blood 130, 3124, 2017
162017
Discovery of JNJ-67856633: a novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
U Philippar, T Lu, N Vloemans, M Bekkers, L Van Nuffel, M Gaudiano, ...
Cancer Research 80 (16_Supplement), 5690-5690, 2020
132020
High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism …
H Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Casneuf, T Smets, ...
Blood 128 (22), 4521, 2016
122016
DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS
U Philippar, T Lu, N Vloemans, M Bekkers, L van Nuffel, M Gaudiano, ...
Hematological Oncology 37, 128-128, 2019
32019
Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions
C Agarinis, V Orsini, P Megel, Y Abraham, H Yang, C Mickanin, V Myer, ...
Journal of Biomolecular Screening 21 (3), 269-276, 2016
32016
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
M Qing, T Zhou, T Perova, Y Abraham, C Sweeney, M Krevvata, X Zhang, ...
Annals of Hematology 103 (6), 1989-2001, 2024
12024
Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants
N Zivanovic, D Öner, Y Abraham, J McGinley, SB Drysdale, ...
Clinical and Translational Medicine 13 (12), e1507, 2023
12023
Understanding the anti-tumor activities of daratumumab in natural killer/T cell lymphoma (NKTCL)
T Zhou, M Qing, Y Abraham, T Perova, C Sweeney, M Krevvata
Cancer Research 81 (13_Supplement), 1023-1023, 2021
12021
The system can't perform the operation now. Try again later.
Articles 1–20